全文获取类型
收费全文 | 80392篇 |
免费 | 6013篇 |
国内免费 | 2524篇 |
专业分类
耳鼻咽喉 | 835篇 |
儿科学 | 1881篇 |
妇产科学 | 1137篇 |
基础医学 | 10325篇 |
口腔科学 | 1506篇 |
临床医学 | 7128篇 |
内科学 | 11966篇 |
皮肤病学 | 2539篇 |
神经病学 | 6031篇 |
特种医学 | 1751篇 |
外国民族医学 | 6篇 |
外科学 | 4939篇 |
综合类 | 11054篇 |
现状与发展 | 7篇 |
预防医学 | 6291篇 |
眼科学 | 972篇 |
药学 | 12456篇 |
32篇 | |
中国医学 | 4089篇 |
肿瘤学 | 3984篇 |
出版年
2023年 | 1150篇 |
2022年 | 1641篇 |
2021年 | 2880篇 |
2020年 | 2625篇 |
2019年 | 2676篇 |
2018年 | 2703篇 |
2017年 | 2627篇 |
2016年 | 2522篇 |
2015年 | 2658篇 |
2014年 | 4696篇 |
2013年 | 5347篇 |
2012年 | 4529篇 |
2011年 | 5130篇 |
2010年 | 4131篇 |
2009年 | 4008篇 |
2008年 | 4035篇 |
2007年 | 3895篇 |
2006年 | 3424篇 |
2005年 | 3210篇 |
2004年 | 2803篇 |
2003年 | 2458篇 |
2002年 | 2054篇 |
2001年 | 1727篇 |
2000年 | 1568篇 |
1999年 | 1407篇 |
1998年 | 1064篇 |
1997年 | 1063篇 |
1996年 | 956篇 |
1995年 | 999篇 |
1994年 | 871篇 |
1993年 | 663篇 |
1992年 | 658篇 |
1991年 | 624篇 |
1990年 | 494篇 |
1989年 | 478篇 |
1988年 | 471篇 |
1987年 | 408篇 |
1986年 | 370篇 |
1985年 | 556篇 |
1984年 | 514篇 |
1983年 | 411篇 |
1982年 | 452篇 |
1981年 | 355篇 |
1980年 | 320篇 |
1979年 | 272篇 |
1978年 | 214篇 |
1977年 | 162篇 |
1976年 | 150篇 |
1975年 | 127篇 |
1973年 | 94篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
21.
22.
23.
24.
《Vaccine》2021,39(45):6601-6613
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. 相似文献
25.
《Vaccine》2021,39(40):5729-5731
IntroductionConcerns were raised over an increase in Bell's palsy, herpes simplex and herpes zoster after BNT162b2 vaccination, all are manifestations of herpesviruses reactivation. As herpesviruses commonly reactivate in the oropharynx, we have hypothesized that oropharyngeal shedding of herpesviruses will increase after vaccination.MethodsImmune-competent Adults, excluding those using topical steroids or manifesting symptomatic herpesvirus infection, were sampled before BNT162b2 vaccination and one week after. Herpesviruses 1–7 shedding was tested with a multiplexed PCR.ResultsIn 103 paired samples the prevalence of herpesviruses was similar before and after vaccination: HSV1, 3.9% vs. 5.8% (p = 0.75); HSV2, 0% vs. 1% (p = not applicable, NA); VZV, 0% vs. 0% (p = NA); EBV, 14.6% vs. 17.5% (p = 0.63); CMV, 0% vs. 0% (p = NA); HHV6, 4.9% vs. 7.8% (p = 0.55); HHV7, 71.8% vs. 72.8% (p = 1); any herpesvirus, 73.8% vs. 74.8% (p = 1).DiscussionWe did not find evidence for increased oropharyngeal reactivation of herpesviruses one week after BNT162b2. 相似文献
26.
27.
28.
29.
6-Mercaptopurine (6-MP) is commonly used for treatment of acute lymphoblastic leukemia (ALL). The incidence of hematotoxicity caused by this drug is quite high in Asians even using a standard low dosage regimen. The present study was aimed to elucidate the impact of thiopurine S-methyltransferase (TPMT), a nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15), inosine triphosphatase (ITPA) and ATP Binding Cassette Subfamily C Member 4 (ABCC4) polymorphisms on hematotoxicity in pediatric patients who received a standard low starting dose of 6-MP. One hundred and sixty-nine pediatric patients were enrolled and their genotypes were determined. Patients who carried NUDT1513 and NUDT1512 genotypes were at a 10–15 fold higher risk of severe neutropenia than those of the wild-type during the early months of the maintenance phase. Risk of neutropenia was not significantly increased in patients with other NUDT15 variants as well as in patients with TPMT, ITPA or ABCC4 variants. These results suggest that NUDT15 polymorphisms particularly, NUDT1513 and NUDT1512, play major roles in 6-MP-induced severe hematotoxicity even when using a standard low dosage of 6-MP and genotyping of these variants is necessary in order to obtain precise tolerance doses and avoid severe hematotoxicity in pediatric patients. 相似文献
30.